标签归档 武汉桑拿按摩论坛

通过admin

Pentium pony strives to create a new life with smart driving, which one is more cost-effective?

Although cars can improve the convenience of people’s travel, safety is still an unavoidable topic. Therefore, many car companies have begun to upgrade the safety of their models. Of course, for consumers, a car with complete active and passive safety configurations will be more popular. The richness of a car configuration is related to the user’s car experience, so many people are concerned about its configuration today. Let’s take a look at it next.

First of all, from the appearance, the design style of Pentium pony head has taken a steady route, which is very sporty. Headlights are simple and fashionable, and the design is more fashionable and dynamic. The car is equipped with etc. Coming to the side of the car body, the size of the car body is 3000MM*1510MM*1630MM, and the car adopts simple lines, which gives people a very streamlined feeling. With large-sized thick-walled tires, the shape is eye-catching. In the design of the rear end, the overall shape of the rear end of the Pentium pony echoes the front face, and the taillights look very comfortable and have a rounded shape.

When I came to the Pentium pony car, the interior shape looked very simple and the overall shape was remarkable. The car looks very good outside the steering wheel, made of plastic, showing a sense of atmosphere. Take a look at the central control. The design of the center console is reasonable, which makes the interior style impressive and has a certain sense of science and technology. The dashboard and seats are equally eye-catching. The dashboard of the car presents a simple design style, highlighting the trendy temperament. The car uses fabric seats, which are wrapped in place and are basically enough for daily use.

Pentium pony matching gearbox, 30KW, 90N.m, good power performance.

The car is equipped with Bluetooth /WIFI connection, sunshade mirror, USB interface, uphill assist, rear reversing radar and other configurations, and the configuration performance is passable and basically satisfactory.

After reading the above introduction, let’s make a summary. Such a car with the right price is enough to meet the daily practical needs, and it doesn’t take much thought to maintain it at ordinary times, and the cost performance is good.

通过admin

Is cell therapy reliable in treating cancer? CAR-T leads the world, and 10 popular and emerging cellular immunotherapy show their magical powers!

The incidence of malignant tumor is increasing year by year, which has become a common problem faced by human beings. Traditional treatment methods such as surgery, traditional chemotherapy and radiotherapy have always played a leading role in cancer treatment, but the effects of these treatments are limited. In particular, it is difficult for advanced patients to benefit from these treatments for a long time, nor can they fundamentally solve or change their quality of life. Therefore, researchers are increasingly focusing on the field of immunotherapy. Immunotherapy has brought new opportunities and hopes for the treatment of tumors, among which Immunocheckpoint inhibitors, therapeutic antibodies, tumor vaccines, immunomodulators, adoptive cell therapy, etc. Significantly improved the prognosis of cancer patients, and some patients with advanced cancer obtained long-term survival. In the past two years, many cellular immunotherapy have emerged and developed rapidly, which undoubtedly set off a wave of cancer treatment. So, is cell therapy reliable in treating cancer? In fact, immunotherapy has a history of more than 100 years, and it has only gradually entered the public’s field of vision in the last two years, and it has been absolutely recognized by the world oncology community.   

20731650935352411   

A milestone in the history of cancer immunotherapy In 2013, Science magazine ranked the top ten scientific breakthroughs of the year, and immunotherapy topped the list. In recent years, immunotherapy is one of the hot spots in the research field of tumor treatment at home and abroad, and a large number of clinical studies have shown exciting results. Among them, Cellular immunotherapy uses the self-protection and killing ability of human immune system to achieve anti-tumor effect. Cells with immune function in patients are cultured and proliferated in vitro, and they are given the ability to attack tumor cells by technical means, and then they are imported into patients to realize their own anti-cancer. This therapyAgainst immune cells, not cancer cells.It is not as harmful to the patient’s health as surgery, radiotherapy and chemotherapy. Patients with early cancer can be treated directly, especially with the attack on residual cancer cells after surgery. Judging from the rapid development in scientific research and clinic in recent years, cellular immunotherapy is expected to become the fourth pillar of anticancer therapy in terms of accuracy, effectiveness and safety. Next, the small series of Cancer-free Home gives a general introduction and inventory of a variety of popular and emerging cellular immunotherapy in the biomedical industry, hoping to give cancer friends a general understanding of the general development process of this cancer treatment field. 

0one  CAR-T cell therapy

CAR-T therapy is chimeric antigen receptor T cell immunotherapy, which is a new precise targeted therapy for treating tumors. T cells are activated by genetic engineering technology, and the positioning navigation device CAR (tumor chimeric antigen receptor) is installed to transform the ordinary "warrior" of T cells into "super warrior" CAR-T cells, Specially identify tumor cells in vivo and kill tumor cells efficiently. So as to achieve the purpose of treating malignant tumors. At present, with 2021, Aquilencel injection, Regioscel injection. It was approved for listing in China, in 2022.Cedarchiorense was approved for listing by FDA.CAR-T therapy is expected to enter the blowout period. Indeed, CAR-T technology has shown good curative effect in many hematological tumors, such as leukemia, lymphoma and multiple myeloma, and more than half of hematologic cancer patients who are on the verge of despair and have no cure have achieved good curative effect.  

29751650935353293

CAR-T cell therapy has been listed at home and abroad at present.

Although the clinical effect of CAR-T therapy on solid tumors is not satisfactory, and it has even been sung down by some people, in recent years, CAR-T therapy has made outstanding progress in the fields of gastric cancer, liver cancer and pancreatic cancer. Scholars at home and abroad have made various modifications to CAR-T, and constantly found new targets for the treatment of various solid tumors.    

Clinical study on CAR-T therapy is out of the loop.

0one Gastric cancer and pancreatic cancer As the first CAR-T cell targeting Claudin18.2 in the world, CT041 emerged as early as the ASCO annual meeting in 2019. At that time, the total objective remission rate was 33.3%, which already surprised the world. Now the more remarkable curative effect is undoubtedly the icing on the cake! This clinical data shows a good treatment prospect for digestive system tumors!

Domestic CAR-T therapy CT041 first appeared in ESMO

Developed by Keji Pharmaceutical at the annual meeting of the European Society of Oncology (ESMO) in 2021.Targeting Claudin18.2(CLDN18.2)Autologous CAR-T candidate productsCT041Showing its presenceDigestive system tumorThe outstanding curative effect can be described as brilliant!

The research data is particularly eye-catching!

1. All patients’The objective remission rate was 48.6%, and the disease control rate was 73%.All patients with gastric cancerThe total objective remission rate was 57.1%.

2. Patients with gastric cancer who failed to receive at least 2 lines of treatment in the past:The objective remission rate was 61.1%, and the disease control rate was 83.3%.

3. And the overall tolerance is good!

As of March 3, 2022,CT041 became the first and only CAR-T cell candidate product in the world for the treatment of solid tumors, which entered the confirmatory phase II clinical trial.This is a milestone for CAR-T to conquer the solid tumor field. Congratulations!

In addition, there are many CAR-T cell therapies targeting CLDN18.2.0 2 liver cancer At present, the clinical trial targets of CAR-T in the treatment of liver cancer are mainlyGPC3 (phosphatidylinositol proteoglycan 3). The breakthrough research results completed by Professor Zhai Bo, director of the Department of Tumor Interventions, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine, were published in the international authoritative journal Clinical Cancer Research on May 5, 2020. By July 24th, 2019, 13 patients had received CAR-GPC3 T cells with a median value of 19.9×108. All the patients are GPC3 positive, and they have received surgical treatment, local treatment or systemic treatment, and they all carry hepatitis B virus (HBV). Two patients achieved partial remission (PR). The 6-month, 1-year and 3-year survival rates of all patients were 50.3%, 42.0% and 10.5% respectively, and the median survival time (OS) was 278 days (39.7 weeks). At the ASCO annual meeting in 2021, Chinese medical researchers published the latest clinical research data of CAR-T drug targeting GPC3 (Ori-CAR-001) in the treatment of recurrent/refractory hepatocellular carcinoma for the first time. As of March 10, 2021, a total of 11 recurrent subjects who received cell infusion were included.All the subjects had advanced hepatocellular carcinoma, and none of them were effective after chemotherapy, TACE (transcatheter arterial chemoembolization) and targeted therapy.Of the 9 evaluable subjects,4 cases achieved partial remission (PR), 3 cases achieved disease stability (SD) and 2 cases developed disease progression (PD).The objective remission rate was 44%, and the disease control rate reached 78%.. 

02  Treatment of tumor infiltrating lymphocytes (TIL)

TILs therapy, simply speaking, is to separate and purify the lymphocytes in the tumor tissue after surgery, select the lymphocytes that can specifically resist cancer, and then amplify and activate them and reinfusion them. This kind of therapy has a history of more than 30 years, and it was first used for malignant melanoma. In recent years, it has given good data in many solid tumors such as cervical cancer and lung cancer.

This therapy is equivalent to pulling back veterans with combat experience directly from the battlefield. After a round of "political review" and "big competition" in professional ability, the spies and traitors are eliminated as far as possible, leaving the ones with the strongest fighting capacity, providing supplies, and then sending them back to the battlefield to continue fighting. Looking at the whole industry, the voice of "innovative therapy based on Tiles cells LN-144 (Lifelecel) is expected to be approved in 2022" is particularly loud. Tiles therapy, as an "ancient" cell therapy, is expected to usher in the first approved product this year, and its great potential in treating solid tumors can not be underestimated, with strong strength and relatively "out of the circle". TILs domain key node event     In 1982  

Steven A.Rosenberg and others discovered for the first time that TILs can inhibit the metastasis of melanoma cells in patients.

  1988  

The earliest attempt of TILs in clinical treatment: TILs therapy for metastatic melanoma achieved an objective remission rate of 60%.

  In 2011  

Steven A.Rosenberg and others published a phase II clinical research data in Clinical Cancer Research: the objective remission rate (ORR) and complete remission rate (CR) of patients with melanoma treated by TILs were 56% and 24% respectively.

  In 2012  

Melinda Bachini, a patient with advanced intrahepatic cholangiocarcinoma, is called the first patient to achieve complete remission (CR) after TILs therapy.

  2019  

At the ASCO meeting, the clinical results of innovative therapies LN-145 and LN-144(Lifileucel) based on TILS cells in the treatment of cervical cancer and melanoma have attracted wide attention in the medical field.FDA awarded LN-145 breakthrough therapy recognition.

  In 2021  

Phase I clinical results of TILs cell therapy at AACR meeting: among 12 evaluable patients.Non-small cell lung cancer patientsMedium,TIL therapy can achieve a total remission rate of 25%, among whichTwo patients achieved lasting complete remission.

  In 2021  

At the annual meeting of tumor immunotherapy association (SITC), the clinical research results of LN-145 in the treatment of metastatic non-small cell lung cancer (mNSCLC) showed that in 28 cases,In patients with recurrent/refractory mNSCLC,After LN-145 monotherapy,The overall remission rate (ORR) was 21.4%(1 case of CR and 5 cases of PR, including 2 cases of PD-L1 negative tumors), 12 cases were stable, and the disease control rate (DCR) was 64.3%.

03  TCR-T therapy

CAR-T cells and TCR-T cells belong to T cells modified by genetic engineering technology.Compared with CAR-T therapy, TCR-T therapy has unique advantages in the field of solid tumor treatment. TCR-T cell therapy can identify tumor-specific antigens from cell membrane surface or intracellular sources, and has entered clinical application from the initial basic immune research, showing initial efficacy in solid tumors, and has become the most likely T cell immunotherapy to make a breakthrough in the field of solid tumors! 

1、 TCR-T cell therapy in China has been approved for clinical use and has become a potential new therapy for HBV-related hepatocellular carcinoma!

At present, in addition to the global TCR-T in full swing in the research and development and clinical verification stage, China is also constantly breaking through innovation.

On December 22nd, 2021, CDE (Drug Evaluation Center) official website was able to inquire about the clinical application of "SCG101 Autologous T Cell Injection", which is a TCR-T cell therapy for specific hepatitis B virus (HBV) epitopes and a potential new therapy for HBV-related hepatocellular carcinoma (HCC).

2881650935354255

▲ Image source: CDE official website

2、 Advanced liver cancer ushered in a new dawn! TCR-T therapy makes cancer patients completely relieved.

As early as 2020 International Hepatology Conference (ILC), ADP-A2AFP, a new TCR-T therapy for liver cancer based on T cells, caused quite a stir, and also made a new breakthrough in the new therapy for liver cancer.

Among the included patients,One patient showed a complete remission (CR) in cancer progression, and the AFP of the other participants also decreased to varying degrees.This means that the experiment has made progress, and it also shows that this therapy is effective for the treatment of advanced liver cancer.

             

10051650935354424

All the 9 patients involved had undergone surgery and conventional radiotherapy and chemotherapy, but failed or became intolerant. Among the 4 patients who received the highest dose of treatment,One patient achieved complete remission, and CT scan showed that all the lesions in the patient disappeared, and it has lasted for more than half a year without any recurrence!

The best response of other patients (cohort 1, cohort 2) is stable. 1 patient in queue 2After one month of treatment, the volume of the primary lesion did not decrease, but the volume of mediastinal lymph node metastasis decreased obviously!       

39351650935354669

Therefore, TCR-T therapy targeting AFP (alpha-fetoprotein) can kill tumor cells expressing AFP. Based on the positive results of this study, researchers are expected to expand the maximum dose to 5 billion cells, and we look forward to the publication of updated data of this study!

04  CAR-NK therapy

In recent two years, in addition to CAR-T therapy, another new cancer cell therapy- Natural killer (NK) cell therapy It has also gradually attracted attention. The researchers said, NK cell As a cell anticancer therapy, it has more potential, and it may be safer, cheaper and faster. CAR-NK is to add a chimeric antibody to NK cells by genetic engineering that can recognize tumor cells and activate NK cells to kill tumor cells at the same time. 

one   The first "spot" CAR-NK clinical trial in China was approved by the Food and Drug Administration. On November 11, 2021, National Medical Products Administration Drug Evaluation Center passed an independent research and development in China. Mesothelin (MSLN) chimeric antigen receptor NK cells (CAR-NK) injection for the treatment of advanced epithelial ovarian cancer. Application for clinical trial of CAR-NK injection. According to the cancer-free home, This product is the first "spot" CAR-NK product of foreign origin in China. This also marks a new milestone in the research of immune cell drugs in the treatment of solid tumors in China! 

2  The 1-year survival rate doubled, and the curative effect of CAR-NK therapy in solid tumor increased sharply.

Recently, the journal Clinical Oncology Research published a phase II clinical trial for lung cancer. Heat shock protein 70(Hsp70) is highly expressed in about 70% of middle and advanced lung cancer. NK cells are activated by Hsp70 in vitro, which is equivalent to making NK cells meet their future enemies in vitro, "making enemies" first, and then returning them to patients, so that NK cells can formally fight with cancer cells in vivo. This method of stimulating NK cells with antigen peptides in vitro and giving them certain specificity is a hot topic in recent years.

A total of 16 patients with stage III non-small cell lung cancer were enrolled in this clinical trial. One group received traditional chemotherapy combined with radiotherapy and chemotherapy, and the other group received chemotherapy combined with Hsp70 pre-stimulated NK cell reinfusion.

The results show that:The one-year survival rate can be doubled from 33% to 67% by Hsp70 pre-stimulated NK cell reinfusion therapy combined with traditional radiotherapy and chemotherapy, and the preliminary results are encouraging.

Next, Xiaobian shows a typical successful case in combination therapy, as shown in the figure:After 1~2 months of treatment, the lung tumor completely disappeared and the curative effect has been maintained for 18 months.

  85441650935355029   

In addition to the above-mentioned clinical studies at home and abroad, CAR-NK cells also have a good effect on glioblastoma and neuroblastoma, specifically recognizing and killing breast cancer cells with high efficiency, and have a remarkable effect on multiple myeloma.

05  Dendritic cell vaccine

Cancer vaccine is a form of immunotherapy, which can prevent cancer from developing or kill existing tumors by stimulating or restoring the human immune system. Dendritic cell (DC) vaccine is a new biological therapy for malignant tumor in recent years, which has been paid more and more attention and recognized by oncologists. As an important member of the human immune defense system, Dendritic cells have the strongest antigen presenting function and are known as "sentinels" of the immune system. It is named because its cells extend outward with many dendritic protrusions. It mainly uses modern high-tech biotechnology to collect the peripheral blood of tumor patients, induce and cultivate a large number of dendritic cells in a short time in vitro, and equip them with immune cells that patients do not have, so as to accurately "target" and kill cancer cells. Not only that, It can also induce immune memory in patients, so that patients can obtain long-term anti-cancer effect.

DCVAC/LuCa is a dendritic cell vaccine developed by the United States for patients with non-small cell lung cancer.In a study on the first-line treatment of advanced lung cancer announced at the ASCO conference in 2019, DCVAC/LuCa vaccine combined with chemotherapy groupThe objective remission rate is 45%,The median overall survival time was 15.5 months, and the median progression-free survival time was 6.74 months.Reduce the risk of death by 46%!

In the Phase II clinical study of the latest novel dendritic cell vaccine DCVAC/LuCa (lung cancer dendritic cell vaccine) combined with standard carboplatin/pemetrexed in the treatment of advanced non-squamous cell (nsq) non-small cell lung cancer in 2022,The 1-year survival rate was 72.73% and the 2-year survival rate was 52.57%.By the time the data was published, the median overall survival time had not been reached. The median progression-free survival time was 8.0 months, and the objective remission rate was 31.82%.

  Prostate cancer-Provenge vaccine  

Provenge is the first vaccine approved for treatment in the United States, which initiated a new era of cancer immunotherapy.This is an autologous cell immunotherapy, which was approved by FDA on April 29, 2010 to treat asymptomatic or mild mCRPC. This approval marks the success of 20 years of unremitting efforts.In the United States, Provenge is the only FDA-approved immunotherapy for prostate cancer made from patients’ own immune cells.

  Ovarian cancer-dcvac/ovca vaccine  

At the 50th annual meeting of the Society of Gynecological Oncology (SGO) in 2019, the final result of SOV02, a phase II clinical trial, was announced: DCVAC/OvCa, an immunotherapy based on dendritic cells, was added to standard carboplatin and gemcitabine schemes for patients with recurrent, platinum-sensitive and epithelial ovarian cancer.It can prolong the overall survival (OS) of patients with advanced recurrent ovarian cancer by more than one year.andDCVAC/OvCa reduced the death risk of second-line treatment of ovarian cancer by 62%. The overall survival (OS) increased significantly by 13.4 months. The median progression-free survival rate (mPFS) increased by 1.8 months. The global phase III study will be launched soon.

Melanoma-TLPLDC vaccine

The subgroup analysis results of the phase IIb clinical trial of TLPLDC vaccine in the treatment of melanoma were published at the ASCO-SITC Clinical Immunooncology Conference in 2020.

In that population analysis follow the clinical research protocol (PT), compared with the comfort unit,The 24-month disease-free survival rate in TLPLDC treatment group was significantly improved (62.9% vs 34.8%), indicating that the relative risk of disease recurrence was reduced by nearly 50%.

In the population analysis of Intentional Treatment (ITT),There was no significant improvement in 24-month disease-free survival between TLPLDC treatment group and placebo group (38.5%) vs 27%),But in this analysis,The improvement trend of 24-month overall survival rate (OS) was stronger (86.4% vs 75.1%)..

  Kidney Cancer-Ilixadencel Vaccine  

Ilixadencel is an allogeneic dendritic cell (DC) vaccine. Research shows that,Ilixadencel combined with targeted anticancer drug sunitinib(Sotan, common name: sunitinib)First-line treatment of newly diagnosed advanced metastatic renal cell carcinoma(mRCC)Compared with patients treated with sunitinib alone, the total remission rate is doubled, the complete remission rate is higher and the remission is more lasting!

  Glioblastoma-AV-GBM-1 vaccine   On June 8, 2021, well-known foreign biomedical companies announced the release of phase II clinical trial data of their personalized cancer vaccine AV-GBM-1. The research shows that this new vaccine has great potential for prolonging the overall survival of newly diagnosed glioblastoma patients in the medium term. The median progression-free survival time of patients was 10.4 months, which was about 50% higher than the median progression-free survival time of 6.9 months in the landmark STUPP study, and established a nursing standard for newly diagnosed glioblastoma patients.     Non-small cell lung cancer-tedopi vaccine  

On April 1st, 2020, a new anti-cancer vaccine, TEDPI, achieved positive results in the phase III clinical trial of non-small cell lung cancer. After the immune checkpoint inhibitor (PD-1) was resistant or failed, all patients in the group used TEDPI vaccine in the second or third line, and the overall survival rate for one year reached 46%, far exceeding the preset 25%!

A 54-year-old patient with advanced lung cancer has rapidly shrunk (from 39mm to 23mm) after five injections of the new lung cancer vaccine. At the time of reporting, his survival time has exceeded 20.6 months, and he is still being followed up.

06  CIK cell therapy

  CIK cells, that is, Cytokine-Induced Killer (CIK), are a new type of immunocompetent cells, which have strong proliferative ability and cytotoxicity, and have certain immune characteristics. Because this cell expresses both CD3 and CD56 membrane protein molecules, it is also called NK cell (natural killer cell)-like T lymphocyte, which has both the strong anti-tumor activity of T lymphocyte and the non-MHC-limited anti-tumor advantage of NK cell. If NK cells are the "first line of defense" to protect human health, then CIK cells are undoubtedly the "precision missiles" to kill tumor cells. Especially for patients after surgery or radiotherapy and chemotherapy, it can eliminate residual tiny metastatic lesions, prevent cancer cells from spreading and recurring, and improve immunity. Therefore, CIK cells are considered as the first choice for a new generation of adoptive cellular immunotherapy for tumors. Research progress of representative CIK cell therapy     

nasal pharyngeal cancer  

Among 137 patients with nasopharyngeal carcinoma treated by CIK, 50% of them improved their survival time by 6-9 months, and among 137 patients treated by CIK, 50% of them delayed their tumor progression by 6-7 months.

32171650935355613

  liver cancer  

Among the 819 patients with liver cancer treated by CIK, 50% of them improved their survival time by 13~25 months, and among the 819 patients treated by CIK, 50% of them delayed their tumor progression by 4~7 months.

87421650935356226

  ovarian cancer  

Among 72 patients with ovarian cancer treated by CIK, 50% of them have improved their survival time by 24 months. Among 72 cases of ovarian cancer treated by CIK, 50% of ovarian cancer patients delayed their tumor progression by 14.5 months.

91721650935356659

 

carcinoma of colon

Among 126 patients with colon cancer treated by CIK, 50% of them have a longer survival time of 30 months. Among 126 patients with colon cancer treated by CIK, 50% of them delayed their tumor progression by 14.5 months.

81471650935357165

  breast cancer  

The probability that the survival time of 150 breast cancer patients treated with CIK can reach 5 years is increased to 85.7%; The probability of keeping breast cancer from recurring in 150 breast cancer patients treated with CIK within 5 years increased to 72.3%.88231650935357798

  Solid tumor  

Of the 31 patients treated with PD-1 antibody combined with DC-CIK, 2 patients’ tumors completely subsided and 5 patients’ tumors partially subsided. Of the above 7 patients, 6 patients’ effects can be maintained for 5 months. The tumors of the other 13 patients remained stable.

13431650935358461

  renal carcinoma  

Among 43 patients with advanced renal cell carcinoma treated by CIK, 50% of them can delay the tumor progression to 14.7 months.

60351650935359231

07  CAR-M therapy 

In recent years, the study of macrophages has also been paid attention to by the industry. How to activate the anti-tumor activity of these macrophages is the direction that immunologists have been working hard. CD47, an immune checkpoint on macrophages, has become a very promising hot target in the field of tumor immunotherapy.

In a recent study published in Nature Biotechnology, researchers from perelman Medical College of the University of Pennsylvania and other research institutions may have an alternative to T cell therapy to overcome these challenges. Their research shows that genetic modification of macrophages (an immune cell that devours intruders in vivo) may be the key to developing effective cell therapy for solid tumors. They were able to confirm these genetically modified expressions. The macrophages of CAR (CAR-M) can kill tumors in human samples and mouse models in the laboratory and prolong their life.   

81441650935359696   

CAR-M therapy is centered on macrophages, which devour invading cells instead of destroying them like T cells. T cells are more like Space Invaders games, while macrophages are more like Pac-Man games. Another major difference between macrophages and T cells is that they are the first responders of the body to virus infection. Historically, this poses a challenge in trying to genetically modify them to attack cancer, because macrophages are not easily transfected by standard viral vectors used in gene therapy and cell therapy.

In this experiment, the research team used genetic engineering technology to transform macrophages. They not only expressed CAR targeting HER2 antigen, but also were activated and differentiated into M1 macrophage types that promoted inflammation. In this way,These CAR-M cells can not only target tumor cells, but also change the microenvironment near tumors by secreting pro-inflammatory cytokines. They can also present tumor antigens to T cells and activate T cells’ immune response to tumors, which can be described as "killing three birds with one stone".

On March 18th, 2021, Carisma Company of the United States announced the completion of the first drug delivery to the subjects of CAR-M therapy (CT-0508) targeting Her2, marking a new era of CAR-M transformation therapy for solid tumors. In a word, taking macrophages as effector cells transformed by CAR is expected to reverse the tumor inhibitory microenvironment, so as to break through the obstacles of immune cell therapy in solid tumors. 

08  CTL (cytotoxic T lymphocyte) therapy

What cell therapy can be used as an adjuvant therapy for the majority of patients with inoperable advanced cancer? In recent years, researchers have been developing new immunotherapy schemes for these patients, including CTL(cytotoxic T lymphocytes) technology. This technology mainly uses protein, which is unique to cancer cells and has no or low content in normal cells, as bait to select the truly anticancer lymphocytes in peripheral blood, and then further improve and amplify them in vitro, and then return them to patients. MTCA-CTL immunotherapy is a new generation of biological immunotherapy model introduced in China. While ensuring the expansion of non-MHC-restricted killer NK-T cells, directional expansion of HC-restricted CD8++specific CTL cells can make its proportion in cell products reach 60% ~ 70%. The combined effect of this killer cell makes the efficiency of killing tumor cells higher.  

10991650935359999

At present, the multi-target compound antigen peptide biological immunotherapy technology, which is undergoing the second phase of clinical trials in the Cancer Hospital of China Academy of Medical Sciences, is the fifth and brand-new generation of cellular immunotherapy technology, which can optimize the activation method of DC (dendritic cells) to enhance the killing effect of immune cells on tumor cells. At present, it has achieved good clinical results and I believe it will really benefit cancer patients.

Mainly suitable for solid tumors.Head and neck tumor, esophageal cancer, lung cancer, gastric cancer, breast cancer, liver cancer, membranous adenocarcinoma, colorectal cancer, ovarian cancer, uterine cancer, coma cancer, prostate cancer, malignant melanoma, sarcoma and partial malignant lymphoma.

If economic conditions permit and you want to consult MTCA-CTL therapy, you can contact.Cancer-free Home Medical Department (400-626-9916), a detailed assessment of the condition.

09  CAR-NKT therapy

  Natural killer T cells (NKT) are a group of special T cell subsets that express both T cell receptors (TCR) and NK cell receptors on the cell surface, and can produce a large number of cytokines. Such as IL-4 and INFγ. These cells can not only directly dissolve and kill tumor cells, but also play an anti-tumor role through indirect ways (secreted cytokines, activated immune cells, etc.). Recently, a phase I clinical trial jointly conducted by Baylor Medical College in Houston and Texas Children’s Hospital is evaluating a new treatment for children with recurrent neuroblastoma –CAR-NKT cell therapy is expected to break through this bottleneck. Phase I trial, code-named GINAKIT2, used CAR-NKT cells for the first time to treat recurrent neuroblastoma. Eleven children (1~21 years old, with an average age of 7 years old) were all recurrent/refractory high-risk neuroblastoma, with extensive metastasis and no better treatment plan in clinic. The results are very encouraging: Of the 11 advanced patients, The condition of 4 patients was stable, 2 patients achieved partial remission (tumor was obviously reduced), and one of them had complete remission (CR) after receiving the second CAR-NKT cell infusion. In safety, CAR-NKT is safer than CAR-T therapy. No dose-limiting toxicity was observed in the first 28 days after infusion. 

10  Compound immune cell therapy

This technology will alsoSix kinds of cells, such as γδT cells, NK cells, NKT cells, killer T cells, dendritic cells and helper T cells.Activate, multiply 10 million to 20 million cells to 2 billion to 5 billion cells, and then inject them into patients. Cultivating such important immune cells at the same time greatly improves the therapeutic effect compared with single treatment.

Except for some leukemia and malignant lymphoma,It can be used for the treatment of most cancers, and has a good effect in refractory cancer types and advanced cancers. Besides,Compound immune cells also play a great role in improving immunity and strengthening the body.

Xiaobian has something to say

In recent years, due to the development of medical level, new cancer treatment methods have appeared one after another, among which cellular immunotherapy is in full swing, which brings new hope to cancer patients. According to the latest statistics, compared with patients with advanced lung cancer, gastric cancer and liver cancer who only receive surgery, radiotherapy and chemotherapy, adjuvant cellular immunotherapy can prolong the survival time of patients and significantly improve the data effect. In fact, tumor treatment is actually a complex "project", and it is difficult to achieve good results by relying solely on a certain treatment method. Tumor treatment needs the cooperation of various treatment methods to achieve the final victory in the fight against cancer. 

通过admin

China released, created a good innovation ecology, and promoted medical technology to better serve people’s lives and health.

China Network April 17 (Reporter Zhang Yanling) Health is an inevitable requirement to promote people’s all-round development, and it is also an important symbol of national prosperity and national prosperity. With the rapid development of economy, society and human civilization, health has become the first demand of the people after China has built a well-off society and solved the problem of food and clothing. The CPC Central Committee attaches great importance to scientific and technological innovation and puts forward that science and technology should "face people’s lives and health".

On April 15th, 2023 China Medical Development Conference was held in Beijing.

Medical science and technology is closely related to people’s health and social well-being, and it is a key factor to promote human health. In order to better serve people’s lives and health, medical science and technology must be innovated, and innovation needs to create a good ecology. So, how to create a good ecology of medical science and technology innovation? On April 15th, at the 2023 China Medical Development Conference held by China Academy of Medical Sciences, the participants discussed the construction of national medical science and technology innovation system and the strategy of creating a good ecology.

Chen Zhu, vice-chairman of the Standing Committee of the 13th National People’s Congress, president of China Red Cross Society and academician of China Academy of Sciences, believes that we should focus on helping to build a healthy China, improving people’s health and well-being, identify the frontiers of medical health science and technology, actively explore the road of new medical education reform, promote the transformation of discipline layout, resource allocation and scientific research ecology, build a good innovative ecology, and make overall plans for innovative layout, so as to contribute wisdom to accelerating the construction of a healthy China and building a healthy human community.

Wang Zhizhen, vice chairman of the 11th Chinese People’s Political Consultative Conference, member of China Academy of Medical Sciences and academician of China Academy of Sciences, believes that the medical science and technology circles in China should be based on the national conditions, take the strategy of healthy China as the guide, dare to challenge the "subversive" problem, accelerate the exploration of the development path of the national modern medical science and technology innovation system, and make innovative contributions to the national medical development.

To create a good ecology of medical science and technology innovation, it is necessary to strengthen supervision. Jiao Hong, member of the 14th Chinese People’s Political Consultative Conference Standing Committee, vice chairman of the 17th Central Committee of the Agricultural Workers’ Party and director of the National Medical Products Administration, believes that entering a new stage of development, it is necessary to benchmark the world’s scientific and technological frontier, strengthen internationally advanced regulatory scientific research, and promote the modernization of drug regulatory system and regulatory capacity, so as to contribute to the high-quality development of China’s pharmaceutical industry and better protect people’s drug safety and health.

Wang Chen, vice president of China Academy of Engineering, academician of China Academy of Engineering, president of China Academy of Medical Sciences, and chairman of academic advisory committee of China Academy of Medical Sciences, believes that to create an innovative ecology of medical science and technology, we should pay attention to "four core elements", namely, academic culture, institutional system, capital resources and international environment, which are finally reflected in the subject of innovation-"people". Therefore, it is necessary to inherit the culture of medical science and technology innovation, improve the system of medical science and technology innovation, establish the mechanism of medical science and technology innovation, expand the resources of medical science and technology innovation, and create an ecological environment of medical science and technology innovation.

Wang Chen said that to create a good medical science and technology innovation ecology, we must establish a good scientific order and value orientation, strengthen academic, scientific and technological cultural construction, and build a scientific medical science and technology evaluation system; Increase investment in innovation in the field of medical health and set up a national medical health science fund as soon as possible; It is necessary to cultivate the innovation ecosystem of clinical and translational medicine and improve the scientific and technological innovation ability of hospitals.

At the same time, it is necessary to strengthen the national medical strategic scientific and technological strength, take the construction of national laboratories and the reorganization of national key laboratories as an opportunity to promote high-level scientific and technological innovation in the field of medical health, strengthen the construction of base platforms, and improve the hierarchical layout of the national medical scientific and technological innovation system; Building the National Institute of Medical Health and China Medical Health Hospital, reflecting the national will and undertaking the national mission, making them the core base and high-end strategic consulting think tank of national medical science and technology innovation, and providing support for improving the overall efficiency of national medical science and technology innovation; Pay attention to the high-level scientific and technological innovation of clinical medicine, pay attention to the cultivation of clinical medicine innovation ecosystem, and continuously enrich the resource pool of top medical scientists in China.

Wang Chen also said that China Academy of Medical Sciences will persist in facing people’s lives and health, make unremitting efforts in academic culture, institutional system, resource fund and international environment, create a fair, responsible, supportive, sustainable and dynamic ecological environment for medical science and technology innovation, promote the construction of a three-dimensional, multi-level, inclusive and cooperative national medical science and technology innovation system and core base, and strive to achieve good interaction with the international medical science and technology community, in order to achieve high-level medical science and technology self-reliance and support medical health.

Zhang Xuemin, a member of the Department of China Academy of Medical Sciences, believes that we should adhere to the correct value orientation and establish the evaluation of outstanding medical science and technology innovation, that is, what have we discovered and invented? What’s the point? Is it true and reliable? The evaluation of scientific and technological personnel should build an evaluation system that is based on "representative works", attaches importance to original innovation and major scientific discoveries, and reflects the country’s major strategic needs, breaks the scientific research routine, realizes the innovation paradigm, promotes mission-driven and interest-driven scientific and technological research with excellent scientific ecology and culture, promotes valuable, true and reliable scientific and technological innovation facing the world’s scientific and technological frontier, and promotes the development of national medical and health undertakings.

Liu Depei, a member of China Academy of Medical Sciences, believes that the core of the framework of medical science and technology innovation system is innovation elements, infrastructure, value creation and institutional environment. The layout of medical science and technology innovation system should make great efforts to promote the innovation of basic theory, the development of biomedical industry, realize the self-reliance of science and technology and improve the level of clinical diagnosis and treatment. National key laboratories, scientific research institutes, medical universities, pharmaceutical enterprises and medical institutions should cooperate with each other and combine their respective advantages to become types of subjects that play different roles. With the support of infrastructure and innovative elements, change the number of base construction, tilt the layout to clinic, coordinate the development of education, science and technology and talent elements, build basic and strategic support, and increase the investment of funds and personnel; With the high-efficiency collaborative medical science and technology innovation network, the multi-agent integrated medical science and technology innovation model is constructed, and the road of medical innovation is opened with system construction as the core, which stimulates the vitality of the main body and enhances the innovation efficiency.

Dong Erdan, a member of China Academy of Medical Sciences, believes that medical science and technology innovation has the characteristics of high risk, high public investment, inherent ethical problems and strict supervision. Therefore, we should adhere to the principle of free exploration and demand-oriented, optimize the structure and layout of medical scientific research in China, take the burden of disease and social demand as traction, solve outstanding scientific problems as driving force, and combine big data analysis to further optimize the allocation and management of medical research resources and promote the formation of a good ecological environment for medical scientific and technological innovation.

Member Wang Xiaofan, member of the Department of China Academy of Medical Sciences, pointed out that developing high-level medical science and technology is the key to building a high-level medical health cause, and it is also a hot field of international science and technology frontier competition and cooperation. In recent years, the international cooperation in medical health in China is increasing day by day, which is helpful to solve the research problems faced by biomedical research. Member Wang Xiaofan suggested further promoting international cooperation with universities, research institutes and academic groups as the main body, helping young scientists to establish more international cooperative relations, taking the lead in organizing global research projects or big science plans, taking China as the main venue, attracting global researchers to jointly study, and providing more China wisdom and Chinese programs for the development of human health.

China Medical Development Conference is an annual platform for China medical circles to discuss and plan the national medical development. Its purpose and function are to unite the national medical science and technology development ideas, lead the national medical science and technology development direction, display the important achievements of China medical science and technology, promote the national medical and health education reform, and promote the high-quality development of the national medical and health undertakings. The annual conference was held on the third weekend of April of that year, and the first conference was held in 2021, which has been held for three times so far.

通过admin

Beijing issued a yellow warning for thunder and lightning, with short-term strong winds and small hail of magnitude 7 and 8 in the local area.

According to the Beijing Meteorological Bureau, it is estimated that there will be thunderstorms in most parts of the city from 17: 00 on the 4th to 02: 00 on the 5th, with strong local short-term rain, accompanied by short-term gale and small hail of magnitude 7 and 8. Please take precautions.

Defense guide

(1) the local people’s governments at all levels, relevant departments and units shall do a good job in lightning protection according to their duties, and organize the inspection of lightning strike hidden danger units or departments;

(2) Parks, playgrounds and other open-air places should stop outdoor facilities and guide visitors to safe places;

(3) Outdoor activities (sports) such as mountaineering, sports, farming, swimming and fishing should be stopped, and buildings with lightning protection devices should be avoided in time;

(4) Don’t take shelter from the rain under big trees, stay away from tall buildings such as towers, chimneys, telephone poles, billboards, etc., don’t stay at the top of the mountain, ridges, roofs, watersides or open areas, and don’t use mobile phones;

(5) Don’t carry an umbrella in the open field, and don’t carry farm tools, badminton rackets, golf clubs, especially objects with metal on your shoulders. You should squat down in low places to reduce your body height.

通过admin

Resume: Luxinshe

  Lu Xinshe, male, Han nationality, born in November 1956 in Juye, Shandong Province, joined the Communist Party of China (CPC) in July 1985, and joined the work in August 1982. He graduated from Wuhan Institute of Water Resources and Electric Power with a bachelor’s degree in irrigation and water conservancy engineering, and is an engineer.

  1978— In 1982, he studied in the Department of Farmland Water Conservancy Engineering of Wuhan University of Water Resources and Electric Power.

  1982— In 1986, cadres of the Land Administration Bureau of the Ministry of Agriculture, Animal Husbandry and Fisheries (during this period: November 1985.11— 1986.08 Studying at the German Training Center of Northwest Agricultural University, Ministry of Agriculture, Animal Husbandry and Fisheries)

  1986— 1990 Director and Deputy Director of the Comprehensive Registry of Cadastral Management Department of the State Bureau of Land Management (during the period: 1987— In 1988, the Federal Republic of Germany Hessian Survey Bureau and Hanover Cadastral Bureau studied; 1989.02— 1989.07 Central Party School, State Organs Branch)

  1990— 1992 Deputy Director, Cadastral Management Department, State Bureau of Land Management

  1992— 1996 Director, Cadastral Management Department, State Bureau of Land Management

  1996— 1998 Deputy Director of the State Bureau of Land Management and Member of the Party Group (1995— In 1996, he was appointed as the deputy mayor of Nantong City, Jiangsu Province)

  1998— 1999 Member of the Party Group of the Ministry of Land and Resources and Director of the Department of Cultivated Land Protection

  1999— In 2009, Deputy Minister of the Ministry of Land and Resources, member of the Party Group, Director of the State Bureau of Surveying and Mapping and Party Secretary (2005— 2008) (during this period: 2000.09— 2000.11 Central Party School Provincial and Ministerial Cadre Training Class)

  2009— In 2010, Deputy Minister of the Ministry of Land and Resources, Deputy Secretary of the Party Group, and Deputy Chief Inspector of State Land

  2010— 2011 Deputy Secretary of Gansu Provincial Party Committee and President of Party School of Gansu Provincial Party Committee

  2011— 2012 Deputy Secretary of Jiangxi Provincial Party Committee and Acting Governor

  2012— 2016 Deputy Secretary and Governor of Jiangxi Provincial Party Committee

  2016— 2018 Secretary of the Jiangxi Provincial Party Committee and Director of the Standing Committee of the Provincial People’s Congress (2017.01)

  2018— In 2019, Secretary of the Party Committee of Guangxi Zhuang Autonomous Region and First Secretary of the Party Committee of Guangxi Military Region (in April 2018)

  2019.01— Secretary of the Party Committee of Guangxi Zhuang Autonomous Region, Director of the Standing Committee of the People’s Congress of the Autonomous Region, and First Secretary of the Party Committee of Guangxi Military Region.

  Alternate member of the 17th Central Committee, member of the 18th and 19th Central Committees. Deputies to the 11th, 12th and 13th National People’s Congress. Member of the 11th Party Committee of Guangxi Zhuang Autonomous Region. Representative of the 13th National People’s Congress of Guangxi Zhuang Autonomous Region.

  (People’s Network information as of January 2019)

通过admin

Reading: Post Bar Create Your Own Post Bar Tutorial Post Bar Create Your Own Post Bar Tutorial

There are so many wonderful contents in Post Bar thanks to the creation of bar owners one by one, but some users don’t know how to operate when they want to create it, so we brought a tutorial to see how to create their own Post Bar.

1, first enter your own post bar, and then click. search box .

2. Then enter the name of the bar you want and click "" Welcome to create xxx. ”。

3. Then you can click on the "" Bar directory ”。

4. After selecting the content you need, click "" accomplish ”。

5. Then click the "below" next step real-name verification ”。

6. Just submit it at last. Successfully created stickers. bar Yes.

 

通过admin

Not the flu! Recently, the symptoms are similar to those of "cold", mostly caused by this virus. ……

When I took the subway recently

It seems that more people wear masks.

Recently, many people have "cold" nasal congestion symptoms.

Many people suspect that it is the flu.

Or mycoplasma infection

In fact, apart from influenza and mycoplasma infection,

The human metapneumovirus has also quietly attacked.

What is human metapneumovirus?

What are the symptoms of infection?

Human metapneumovirus infection is increasing gradually.

Recently, the China Center for Disease Control and Prevention released the national monitoring of respiratory infectious diseases, and acute respiratory infectious diseases showed a continuous upward trend, among which human metapneumovirus infection gradually increased.

What is human metapneumovirus? Human metapneumovirus is a common virus that can cause acute respiratory infection. Compared with traditional respiratory infection viruses such as influenza, human metapneumovirus is relatively "young" and its discovery time is late. In 2001, Dutch scholars first detected the virus from nasopharyngeal aspirate samples of children with respiratory tract infection caused by unknown pathogens. Although it was discovered late, serological studies show that it has existed in humans for more than 60 years and is distributed all over the world.

How does human metapneumovirus spread? The mode of transmission of human metapneumovirus is similar to that of most respiratory viruses, mainly through the following channels:

1. droplet transmission: when an infected person coughs or sneezes, the virus will spread with droplets;

2. Contact transmission: close contact with people infected with metapneumovirus, or contact with objects contaminated by metapneumovirus (such as doorknobs, mobile phones, toys, etc.), and then touch your eyes, nose or mouth, causing the virus to enter the body.

However, it should be noted that human metapneumovirus has certain viability in the environment, especially on the surface of objects, and the virus can survive for several hours. Therefore, it is very important to do a good job in daily life.

Authorized map, reprint is risky.

This virus is easily infected by the whole population.

Human metapneumovirus usually occurs in winter and spring because it is dry and easy to spread in winter and spring. The whole population is generally susceptible to human metapneumovirus, and patients are the most contagious at the beginning of the disease. The immune protection time of patients is relatively short, and they are prone to repeated infection. It should be noted that the patient’s incubation period and terminal illness are contagious after infection.

The incubation period of human metapneumovirus infection is generally 3-6 days, and the symptoms of human metapneumovirus infection are similar to those of influenza, but the main manifestations of human metapneumovirus infection are colds, fever, cough, runny nose and other symptoms, while influenza virus will have high fever and general fatigue.

Authorized map, reprint is risky.

1. Common symptoms: upper respiratory tract infection symptoms such as cough, fever, nasal congestion and shortness of breath;

2. Mild infection: For most people, human metapneumovirus infection is a self-limited disease, and most people gradually relieve their symptoms in about 1 week;

3. Severe infection: For the following high-risk groups, human metapneumovirus may cause severe lower respiratory tract infection:

① Children under 5 years old: it may lead to bronchiolitis or severe pneumonia;

② Elderly people: It may induce lung infection or aggravate asthma;

③ People with low immunity: For example, those who receive organ transplantation or hematopoietic stem cell transplantation may have severe lung inflammation after infection.

It should be noted that at present, there are no specific drugs and vaccines for human metapneumovirus infection, and symptomatic support treatment is the main one.

During illness, it is necessary to ensure adequate energy and nutrition intake, pay attention to the balance of water and electrolyte, and maintain internal environment stability. Blind or improper use of antibacterial drugs, especially the combination of broad-spectrum antibacterial drugs, should also be avoided. Virus infection is often not complicated with bacterial infection in the early stage.

After being infected with the virus, you can pay close attention to the changes of your condition. Once you have symptoms such as dyspnea and persistent high fever, you should seek medical advice in time and use drugs rationally under the guidance of a doctor.

How to prevent human metapneumovirus infection

Because the mode of transmission of human metapneumovirus is similar to that of most respiratory viruses, we can:

Good habits: Develop good hygiene habits such as washing hands frequently, wearing masks and cleaning frequently.

Regular ventilation: open the window regularly every day to keep the indoor air fresh and unobstructed.

Less gathering: Try to avoid places where people gather or where the space is closed.

Improve immunity: eat a balanced diet, exercise moderately, work and rest regularly, and keep healthy.

Authorized map, reprint is risky.

In a word, keeping good living habits, wearing masks when going to crowded places, and taking preventive measures such as frequent hand washing, frequent ventilation and scientific disinfection can effectively reduce the chance of infection.

Want to receive more popular science knowledge in time

Set "Guangdong popular science" as a star sign ~

↓↓↓

Recommended video today

Don’t be a "mushroom" brave man

Wild mushrooms are famous for their unique delicacy and mystery.

However, there is a risk of poisoning when eating wild mushrooms.

There is a fatal hazard

There are many misunderstandings in the method of identifying poisonous mushrooms by network.

There is no shortcut to identify poisonous mushrooms.

The key to prevent poisoning is not to eat strange wild bacteria at will.

Eat bacteria rationally,

Don’t be a "mushroom" brave man

Popular reading

(Click on the picture to read)

Original title: "Not the flu! Recently, the symptoms are similar to those of "cold", mostly caused by this virus …

Read the original text

通过admin

Ministry of Commerce: China vigorously develops digital trade and digital economy, and the international circle of friends continues to expand.

  Cctv newsOn the afternoon of September 7, the Ministry of Commerce held a press conference to introduce the recent key work in the business field and answer reporters’ questions.

  He Yadong, the new spokesperson, introduced that the important exposition of the Supreme Leader General Secretary on developing digital economy and digital trade should be thoroughly implemented, and various measures should be taken to promote the digital development in the business field.

  First, vigorously develop digital trade. Promote the introduction of policies and measures to promote the reform, innovation and development of digital trade, strengthen and improve the national digital service export base, promote the establishment of the Digital Trade Standardization Technical Committee of the Ministry of Commerce, strengthen international cooperation in digital trade, and sign a memorandum of understanding on cooperation in the field of digital trade with the economic and trade departments of five Central Asian countries. In 2022, China’s import and export volume of digitally deliverable services reached US$ 372.7 billion, up 3.4% year-on-year, ranking fifth in the world.

  The second is to speed up the digital transformation of domestic trade circulation. Strengthen the role of demonstration and create a total of 170 national e-commerce demonstration bases; Vigorously develop rural e-commerce and further promote the number of merchants to promote agriculture; Actively promote online consumption, the national physical online retail sales accounted for more than 26% of the total retail sales of consumer goods.

  The third is to improve the digital level of trade and investment. The proportion of cross-border e-commerce in the total foreign trade has increased from less than 1% in 2015 to 5% in 2022. The digital economy-related content in the negative list of foreign investment access has been revised many times, and the conditional free trade pilot zone has been promoted to connect with international high-standard digital economy rules.

  The fourth is to promote international cooperation and rule-making in the digital field. Actively expand and deepen the "Silk Road E-commerce" cooperation, and have established bilateral e-commerce cooperation mechanisms with 29 countries. Signed a memorandum of cooperation on digital economy and investment with 18 countries, and a number of digital enterprises successfully went to sea.At present, among the 21 free trade agreements signed by China, 10 have set up special chapters on e-commerce or digital economy, and the circle of international friends in digital economy has been expanding.

  Digital trade, trade in goods and services have become the three pillars of a powerful trading country. As the only national, international and professional exhibition with the theme of digital trade in China, Global Digital Trade Expo is a powerful starting point to promote the reform, innovation and development of digital trade, which is conducive to linking all parties to jointly build markets, promote growth, discuss cooperation and share achievements, and contribute wisdom and strength to the development of global digital trade.

  The second Digital Trade Fair will be held in Hangzhou, Zhejiang Province from November 23 to 27. It will be co-sponsored by the Ministry of Commerce and Zhejiang Province. With the theme of "digital traders connect with the world" and the characteristics of "integrated operation and integration of numbers and facts", it will set up four sections: conference, exhibition, platform and activities, and build a comprehensive pavilion, two characteristic pavilions of frontier trends and Silk Road e-commerce, digital technology, digital services, digital content and

通过admin

In the first seven months, the import and export of goods increased by 10.4% year-on-year.

On August 7, the General Administration of Customs released data showing that in the first seven months of this year, the total import and export value of China’s goods trade was 23.6 trillion yuan, up 10.4% year-on-year. Among them, the export was 13.37 trillion yuan, a year-on-year increase of 14.7%; Imports reached 10.23 trillion yuan, a year-on-year increase of 5.3%.

Since the beginning of this year, in the face of the complicated and ever-changing international environment, China has effectively coordinated epidemic prevention and control and economic and social development, and foreign trade has overcome many adverse effects and achieved rapid growth.

Optimization of foreign trade structure

In the first seven months of this year, the growth rate of China’s foreign trade accelerated, and the quantity and quality rose together, mainly showing the following characteristics-

The import and export of general trade increased and its proportion increased. In the first seven months, China’s general trade import and export was 15.17 trillion yuan, up 14.5%, accounting for 64.3% of China’s total foreign trade, up 2.3 percentage points over the same period last year. China’s import and export by bonded logistics was 2.87 trillion yuan, an increase of 9.3%. Among them, exports were 1.08 trillion yuan, up by 15.6%; Imports reached 1.79 trillion yuan, up 5.9%.

Exports of mechanical and electrical products and labor-intensive products both increased. In the first seven months, China exported 7.57 trillion yuan of mechanical and electrical products, an increase of 10.1%, accounting for 56.6% of the total export value. Among them, mobile phones were 494.63 billion yuan, an increase of 2%; Automobile was 175.74 billion yuan, up by 54.4%. In the same period, the export of labor-intensive products was 2.41 trillion yuan, an increase of 15.2%, accounting for 18%.

In terms of commodities, the import price of iron ore has fallen, while the import price of crude oil, coal, natural gas and soybeans has dropped. In the first seven months, China imported 627 million tons of iron ore, down by 3.4%, and the average import price was 835.1 yuan per ton, down by 27.8%. In the same period, China imported 290 million tons of crude oil, down 4%, and the average import price was 4,736.1 yuan per ton, up 58.3%.

From the monthly data, in July, China’s total import and export value was 3.81 trillion yuan, an increase of 16.6%. Among them, exports were 2.25 trillion yuan, an increase of 23.9%; Imports reached 1.56 trillion yuan, up by 7.4%; The trade surplus was 682.69 billion yuan, up by 90.9%.

"The trade surplus reflects that China’s foreign trade has strong competitiveness in the context of the expected decline in global economic growth." Zhang Jianping, deputy director of the Academic Committee of the Institute of International Trade and Economic Cooperation of the Ministry of Commerce, told this reporter that a series of policies and measures to stabilize foreign trade, including tax reduction and fee reduction, inclusive finance and export tax rebate, have helped foreign trade enterprises overcome difficulties, achieved high-quality foreign trade development, stabilized economic growth expectations and boosted confidence.

RCEP dividend appears

From a regional perspective, foreign trade in the Yangtze River Delta region has continued to recover rapidly. In the first seven months, the import and export of three provinces and one city in the Yangtze River Delta region increased by 11.7% year-on-year, 2.5 percentage points faster than that in the first half of the year; In July, it increased by 25.7% year-on-year, contributing more than 50% to the national foreign trade growth.

In terms of major trading partners, in the first seven months, ASEAN, the European Union, the United States and South Korea were China’s top four trading partners, with imports and exports of 3.53 trillion yuan, 3.23 trillion yuan, 2.93 trillion yuan and 1.39 trillion yuan respectively, up by 13.2%, 8.9%, 11.8% and 8.9% respectively. ASEAN continues to be China’s largest trading partner, accounting for 15% of China’s total foreign trade.

Since the Regional Comprehensive Economic Partnership Agreement (RCEP) came into effect on January 1 this year, dividends have been continuously released. In the first seven months, the import and export of China and other 14 member countries of RCEP increased by 7.5% year-on-year.

Li Kuiwen, director of the Statistics and Analysis Department of the General Administration of Customs, said: "In July, China’s import and export to RCEP trading partners was 1.17 trillion yuan, up 18.8% year-on-year, driving the overall import and export growth by 5.6 percentage points. RCEP came into effect this year, further deepening regional economic interconnection and trade and investment cooperation, and providing new kinetic energy for regional economic recovery and development. "

Zhang Jianping suggested that in the future, we should make good use of the advantages of 21 pilot free trade zones and Hainan Free Trade Port, seize the new opportunities brought by RCEP, continuously expand the foreign trade market, and give full play to the role of foreign trade in promoting economic growth.

The proportion of foreign trade of private enterprises has increased.

With a series of policies and measures to help enterprises get rid of difficulties, the vitality of foreign trade market players has been effectively stimulated. Data show that in the first seven months, the number of foreign trade enterprises with import and export performance in China was 526,000, an increase of 5.8% year-on-year.

The proportion of foreign trade of private enterprises has increased. In the first seven months, the import and export of private enterprises was 11.8 trillion yuan, up 15.3%, accounting for 50% of China’s total foreign trade, up 2.1 percentage points over the same period last year, and continued to play the role of "main force" in foreign trade. Among them, exports reached 8.01 trillion yuan, up 20.9%, accounting for 59.9% of the total export value; Imports reached 3.79 trillion yuan, up 5%, accounting for 37% of the total import value.

In the same period, the import and export of foreign-invested enterprises was 7.97 trillion yuan, up 2.7%, accounting for 33.8% of China’s total foreign trade. Among them, exports were 4.3 trillion yuan, an increase of 6.4%; Imports were 3.67 trillion yuan, down 1.4%. The import and export of state-owned enterprises was 3.8 trillion yuan, up by 15.5%, accounting for 16.1% of China’s total foreign trade. Among them, the export was 1.05 trillion yuan, up by 10%; Imports reached 2.75 trillion yuan, up by 17.8%.

Li Kuiwen said: "The state has introduced a package of policies and measures to stabilize the economy and support enterprises to solve problems. The Customs has also specially studied and introduced seven measures to help enterprises get rid of difficulties and reduce costs, so as to effectively solve practical problems for enterprises. With the effectiveness of these measures, the vitality of foreign trade market players has been effectively stimulated. In the first seven months, the import and export of various foreign trade entities maintained growth, which effectively promoted the stability and quality improvement of China’s foreign trade. "

Looking forward to the next stage, Li Kuiwen said that the fundamentals of China’s strong economic resilience, sufficient potential and long-term improvement have not changed. With the further implementation of the national package of policies and measures to stabilize the economy and the orderly resumption of work and production, China’s foreign trade is still expected to continue to maintain steady growth. (Reporter Xu Peiyu)

通过admin

On canceling the "anti-routine" of the 2020 national examination questions of big composition

On November 24, 2020, the written examination for civil servants of the central organs and their directly affiliated institutions began. This is the national examination center located in Chengdu University of Information Science and Technology.

  Welcome the light snow in winter, such as the national examination. On the morning of November 24th, 2020, the written examination for civil servants of central organs and their directly affiliated institutions began. According to the official data released earlier, the national examination plans to recruit 24,000 people, involving 86 units and 23 directly affiliated institutions of the central and state organs, with a total of 1.437 million people passing the qualification examination, and the ratio of the number of qualified people to the number of employment plans is about 60: 1.

  — — This is also the 12 consecutive years, and the number of applicants for the national examination has exceeded one million.

  This is almost the exam with the highest national participation except the college entrance examination, and the overall admission rate of 1.68% is as difficult as that of Tsinghua Peking University. In Sichuan, there were 35,646 candidates in the examination area, and 28,218 actually took the examination, with a reference rate of 79.2%, which was higher than that in the national examination in 2019, but there were still 7,428 candidates who passed the qualification examination and stood up.

  Focus 1

  2315:1

  The fiercest competition for the hottest position is reduced.

  In the past three years, the national examination has experienced a ups and downs in the number of people enrolled in the plan.

  In the national examination in 2018, it is planned to recruit more than 28,000 people. In the end, 1,659,700 people passed the qualification examination, an increase of 173,400 compared with 2017, and the ratio of the number of people who passed the qualification examination to the number of employment plans was 58: 1.

  In the national examination in 2019, it is planned to recruit 14,500 people, and a total of 1,379,300 people passed the qualification examination. The average competition ratio reached 95: 1, the highest in the previous five years, and the competition for the hottest positions exceeded 4,000: 1.

  By this year, it is planned to recruit about 24,100 people, and a total of 1.437 million people have passed the registration qualification examination, and the ratio of the number of qualified people to the number of employment plans is about 60: 1.

  It can be seen that from the total number of people enrolled in the plan, although this year has greatly increased compared with the recruitment plan of more than 14,500 people last year, the ratio of 60: 1 is still fierce.

  On the other hand, the hottest position this year is the first-level chief clerk of the Reproduction Department of China No.1 Historical Archives and below. This position recruits one person, with a competition ratio of 2315: 1, but compared with the competition ratio of 9837: 1 of the hottest position in 2017, the popularity has been greatly reduced.

  In addition, a total of 19 Sichuan-related departments participated in the recruitment examination in this national examination, including Chengdu Customs, Chengdu Railway Public Security Bureau, Sichuan Supervision Bureau of the Ministry of Finance, etc. A total of 676 posts were announced and 942 people were recruited. As of one hour before the end of the registration, a total of 49,313 applicants have applied for positions in Sichuan departments, and 40,054 people have passed the trial.

  Among them, the most fierce competition is that the first three positions are tax departments. They are the first-class administrative law enforcer (1) of Leibo County Taxation Bureau in State Taxation Administration of The People’s Republic of China, the first-class administrative law enforcer (3) of jinniu district Taxation Bureau in Chengdu, State Taxation Administration of The People’s Republic of China and the first-class administrative law enforcer (2) of Leibo County Taxation Bureau in State Taxation Administration of The People’s Republic of China.

  As of one hour before the end of registration, the competition ratio has been "one thousand people vying for one job".

  Focus 2

  Examination questions "anti-routine"

  In the graded examination, the big composition was replaced.

  As an important examination for selecting talents for the country, the scientific setting of national examination questions has been constantly explored. In this year’s announcement, it was clearly pointed out in the first year that "the written examination of public subjects will make test questions for the positions of the central organs and their provincial-level directly affiliated institutions, and the positions of the municipal (prefecture) level and below directly affiliated institutions".

  "The national examination is really getting harder and harder. I feel that I can’t go to the routine, but I have to learn and accumulate. "Zhao Ling, a candidate, was a little depressed when she walked out of the examination room. This is her third year to participate in the national examination. The latest time, she was only two places away from entering the interview.

  She told reporters that in her opinion, the difficulty of the morning test was similar to that of previous years, among which the old man Zhang Fuqing, a model of the times, was admitted. But the problem of graphic reasoning is much more difficult, and I don’t know how to start at all. At the end of the last half hour, even an old hand like her felt a little flustered.

  The real "anti-routine" is the application in the afternoon. Many candidates told reporters that it was a bit awkward to hold the question. "Is the big composition gone?" “

  This year, the examination questions of prefecture-level cities involve putting forward solutions and measures for farmers’ markets, writing an introduction outline for smart communities in the district, and writing a recommendation material for local villages.

  The provincial and ministerial examination questions are related to the introduction of talents. "The topic is not new, but it is difficult to find the angle. "One candidate admitted that he had memorized the composition template and" universal golden sentence "before the exam, and the result was useless at all.

  "The main test is the overall quality and potential ability of the candidates, and they care more about a cumulative process than a surprise attack before the exam. "In response to the national examination questions, a professional who has been engaged in relevant training for a long time said that the threshold for entering the national examination is improving, and the recruitment conditions for many positions have become more stringent in different aspects. At the same time, the examination questions are constantly innovating in form. It is necessary to examine the overall quality of the applicants and play a selective role.

  Focus 3

  Don’t judge people by their differences.

  Appropriate tilt for special areas and positions

  It is worth noting that in addition to the exploration of classification and grading in written examination, the national examination is also constantly exploring the "morality" and "politics" of candidates and constantly optimizing the selection methods.

  For example, in 2011, the national examination began to sign a letter of good faith, and in 2016, efforts were intensified to crack down on cheating in the examination. In 2017, it was further clearly pointed out that the work would be further strictly inspected. This year, on the basis of previous years, the number of people who have been expelled from the Communist Party of China (CPC) Party membership and those who have been listed as joint disciplinary targets for dishonesty in accordance with the law have been specially increased, and they are not allowed to enter the examination.

  At the same time, in the inspection session, this year, it was particularly pointed out that "the inspection work highlights political standards and adopts methods such as individual talks, field visits, strict examination of personnel files, inquiry of social credit records, and personal interviews, focusing on understanding the political beliefs, political positions, political awareness and political performance of the candidates. Some recruitment agencies at the central level carry out the difference inspection, and select the best candidates according to the principle of matching people with posts, not just selecting people. “

  On the other hand, after the written examination of the national examination is finished, the central civil servant department will study and determine the minimum qualified scores for written examinations of various positions, and will appropriately tilt the positions in the western region and hard and remote areas, grassroots positions and special professional positions.

  Next, candidates can log on to the special website of examination records in January 2020 to check the written test scores and the minimum qualified scores.

  Among them, the written test scores of 8 non-common language positions are synthesized according to the proportion of 25%, 25% and 50% of the administrative professional ability test, application and foreign language proficiency test respectively. The written test scores of the special professional positions in China Banking and Insurance Regulatory Commission and its dispatched offices in China and the special professional positions in China Securities Regulatory Commission and its dispatched offices were synthesized according to the proportion of 25%, 25% and 50% of the written test scores of administrative professional ability test, application and professional subjects respectively. The positions of people’s police in public security organs are synthesized according to the proportion of 40%, 30% and 30% of the scores of administrative professional ability test, application and written examination of professional subjects respectively.